Should I buy Chemours (CC) stock or is it too late?
No reliable analyst is bullish on this stock right now. A “reliable” analyst is a firm that, on this sector, hits more than 55% of its targets and beats its sector. None of them sees upside here — which is exactly why this stock is in no JPI selection.
Firm-by-firm track record on Chemours
| Firm | % right | Gain vs sector | Calls | Aims for |
|---|---|---|---|---|
| BMO Capital | 40 % | +1.8 % | 20 | $18 +13% |
| RBC Capital | 50 % | +0.0 % | 14 | $22 +39% |
| UBS | 17 % | -58.1 % | 6 | $18 +13% |
| Citigroup | 20 % | -33.5 % | 5 | — |
✅ Reasons to believe
- Median price target $21, i.e. +32% from the current price ($16).
- The most reliable firm on CC, Goldman Sachs (100% hit rate, 2 scored calls), targets $18 (call made on February 25, 2026, maturing on February 25, 2027) (+13%) in its most recent call.
⚠️ Reasons to hesitate
- The consensus is not unanimous: of 7 ratings, 3 are neutral.
- A 12-month target is not a guaranteed path: the price can fall in the meantime.
- No dividend: your return depends only on price appreciation.
The analyst consensus on CC
Median target $21 (+32%) · 7 ratings · Buy consensus
⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.
Frequently asked questions
Should you invest in Chemours now?
We won't decide for you. The facts: 57% of analysts rate it a buy, median target $21 (+32%), and Goldman Sachs (most reliable on CC, 100%) targets $18. Weigh that against valuation. This is not personalized advice.
Is it too late to invest in Chemours?
Not according to analysts: the median target ($21) is still +32% above the current price ($16) (most reliable on CC: Goldman Sachs, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.
Is Chemours still worth investing in?
It depends on the gap between the price ($16) and its estimated value: analysts target $21 on median (+32%), with 57% buys (most reliable on CC: Goldman Sachs, 100%). Cross-check with their real reliability on CC and the cautions above. Information, not advice.
What's the main risk in buying CC?
The consensus is not unanimous: of 7 ratings, 3 are neutral.
→ Go deeper: the full Chemours profile (consensus, analyst reliability, price target, performance).